Recent Advancements and Developments of Anti-Malarial Agents Reported in 2023

Malaria, caused by Plasmodium falciparum and other species, remains a significant global health issue, transmitted by infected Anopheles mosquitoes. According to the WHO 2024 report, malaria affected 249 million individuals and resulted in 608,000 deaths between 2000 and 2022. The rise of drug resistance in both Plasmodium species and Anopheles mosquitoes has significantly complicated the malaria treatment, necessitating the development of novel therapeutic agents. This review highlights recent advancements in the design of anti-malarial drugs, with a particular focus on heterocyclic compounds reported in 2023, in continuation of our previous works on updates on anti-malarial agents reported since 2016. Among these, artemisinin derivatives have shown remarkable efficacy, while other heterocyclic classes-such as benzofuran, β-lactam, coumarin, indole, morpholine, piperazine, pyrimidine, pyrrole, quinazoline, quinoline, thiazole, and triazoles-are emerging as promising alternatives. These compounds target essential parasite functions such as heme metabolism, RBC invasion, and oxidative stress pathways, with several new hybrid molecules combining multiple mechanisms of action to counter drug resistance. This review provides an overview of recent developments in these heterocyclic-based anti-malarial agents, summarizing their chemical structures, mechanisms of action, and therapeutic potential. By focusing on innovations reported in 2023, this study aims to orient the ongoing research in the pursuit of safer and more effective treatments for malaria.